Clinical research is at the heart of all medical advances and contributes greatly to improving the quality of medicine that is available to you and your loved ones. Participants in research studies—people just like you—are a critical link in making these discoveries possible.
Both ARC patients and non-ARC patients who fit trial eligibility requirements are welcome.
New enrolling studies
- BaxDuo Pacific Chronic Kidney Disease (CKD) Clinical Study: A phase III, randomized, double-blind, active-controlled study intended to assess the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease (CKD) progression and cardiovascular events in participants with CKD and high blood pressure.
- Chronic Spontaneous Urticaria (CSU) Clinical Study: A multi-center, phase 2b, randomized, placebo-controlled, dose-ranging study evaluating the efficacy and safety of EV0756 in subjects with moderate to severe CSU (chronic spontaneous urticaria).
All enrolling studies
Learn more by calling ARC Clinical Research at 737-247-7240 or visit ARCclinicalresearch.com.